newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTX
  • AN2 Therapeutics advanced its oral epetraborole program for polycythemia vera toward a Phase 2 trial expected to initiate in Q3 2026.
  • An investigator-initiated Phase 2 trial of epetraborole for M. abscessus lung disease commenced in March 2026 with top-line data anticipated in late 2027.
  • Phase 1 first-in-human & non-human primate efficacy data for oral AN2-502998 (Chagas disease) are expected in Q2 2026.
  • The Company declared its ENPP1 candidate for solid tumors, transitioning the program from early research into development.
  • First quarter 2026 Research & Development expenses were $6.7 million, down from $7.7 million in the same period in 2025.
  • First quarter 2026 General & Administrative expenses were $3.8 million, matching the prior year period.
  • The Company reported a net loss of $10.0 million for Q1 2026, compared to $10.6 million in Q1 2025.
  • Cash, cash equivalents, & investments totaled $85.3 million as of March 31, 2026, following a $40.0 million private placement in March 2026.
  • AN2 Therapeutics projects its cash runway will sustain operations into 2029 under the current operating plan.
  • The Company plans to advance three programs into Phase 2 development during 2026.